Pediatric Nephrology
51 – 60 of 134
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2013
-
Mark
Ouabain Protects against Shiga Toxin-Triggered Apoptosis by Reversing the Imbalance between Bax and Bcl-xL
(
- Contribution to journal › Article
-
Mark
Complement activation in thrombotic microangiopathy.
(
- Contribution to journal › Scientific review
-
Mark
Neonatal onset atypical hemolytic uremic syndrome successfully treated with eculizumab
(
- Contribution to journal › Article
-
Mark
Eculizumab in an anephric patient with atypical haemolytic uraemic syndrome and advanced vascular lesions.
(
- Contribution to journal › Article
-
Mark
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
(
- Contribution to journal › Article
-
Mark
Complement Activation Associated with ADAMTS13 Deficiency in Human and Murine Thrombotic Microangiopathy.
(
- Contribution to journal › Article
- 2012
-
Mark
The Antimicrobial Peptide Cathelicidin Protects Mice from Escherichia coli O157:H7-Mediated Disease.
(
- Contribution to journal › Article
-
Mark
Escherichia coli O104:H4 and Hemolytic Uremic Syndrome: The Analysis Begins
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Novel C3 Mutation Causing Increased Formation of the C3 Convertase in Familial Atypical Hemolytic Uremic Syndrome.
(
- Contribution to journal › Article